TABLE 1.
Patient demographic and clinical data for samples included in study, Chris Hani Baragwanath Academic Hospital haematology laboratory, Johannesburg, South Africa, 2012–2013 (N = 149).
| Parameter | All patients (N=149) | HIV-positive (n=79) | HIV-negative (n=70) |
|---|---|---|---|
| Age (years) (median [IQR]) (n = 147) | 40 (30–52)† | 38 (31–45) | 47 (22–58)‡ |
| CD4 count (× 106/L) (median [IQR]) (n = 52) | 129 (39–331) | 129 (39–331) | N/A |
| HIVVL (copies/mL) (median [IQR]) (n = 30) | 150 (40–86 910) | 150 (40–86 910) | N/A |
| ART (yes/no) | 35/8 | 35/8 | N/A |
| History of malignancy (n [%]) | 61 (41.6) | 35 (44.3) | 26 (36.6) |
| High-grade lymphoma (n [%]) | 23 (37.7) | 22 (62.9) | 1 (3.8) |
| Acute leukaemia (n [%]) | 12 (19.7) | 2 (5.7) | 10 (38.5) |
| Chronic myeloid leukaemia (n [%]) | 11 (18.0) | 5 (14.3) | 6 (23.1) |
| Low grade lympho-proliferative disorders (n [%]) | 5 (8.2) | 1 (2.9) | 4 (15.4) |
| Other (n [%]) | 10 (16.4) | 5 (14.3) | 5 (19.2) |
| Recent chemotherapy | 43 (28.9) | 20 (25.3) | 23 (32.4) |
| Malignant cells in the blood (n [%]) | 17 (11.4) | 8 (10.1) | 9 (12.7) |
| Evidence of infection (n [%]) | 48 (32.2) | 33 (41.8) | 15 (21.1) |
WCC, White cell count; IQR, Interquartile range; N/A, not applicable; HIVVL, HIV viral load; ART, anti-retroviral therapy.
†
n = 147 (age was not provided for two patients);
‡
n = 69.